NOAH GeparQuinto
NeoAltto
CHER-LOB
NSABP B-41
Scheme
Ch
+
T
Ch
+
T
Ch
+
L
Ch
+
T
Ch
+
L
Ch
+
TL
Ch
+
T
Ch
+
L
Ch
+
TL
Ch
+
T
Ch
+
L
Ch
+
TL
Primary
endpoint
EFS
pCR breast
& axilla*
pCR breast
pCR breast &
axilla
pCR breast
n
115
307
308
154
149
152
36
39
46
177 171 171
pCR (%)
breast
43
50
35
29
25
51
NR NR
NR
52
53
62
pCR (%)
breast & axila
38
31
22
28
20
47
26
29
43
49
47
60
Neoadjuvant Studies II
*pCR excludes ducatl in situ carcinoma
Ch, chemotherapy; EFS, event free-survival; L, lapatinib; n, sample; pCR, pathological
complete response; T, trastuzumab
